Drug discovery platform: HUB Organoids serve as an ideal platform for drug discovery screens, target discovery, and genomic and functional studies at a scale that could never be achieved for clinically relevant models.
Drug development: HUB Organoids provide drug efficacy, safety and mechanistical data. Furthermore, disease specific collections of Organoids enables pre-clinical stratification of patient populations.
The reason why individual patient, during a clinical trial of new treatments performed by pharma industry, respond or not to the treatment is almost always unclear. Only when very specific biomarkers are known do we have an indication why treatments are successful or not. Organoids can serve as the ultimate biomarker because they can be generated of each patient in the trial. In vitro tests of these patient organoids will demonstrate if the lab response correlates to the clinical response, successful or not. The organoid therefore will serve as a tool to identify the mechanism underlying success and failure and/or serve as a companion diagnostic in case of success if the treatment.
HUB has created Organoid biobanks from patient material that capture disease heterogeneity in diseases such as Cancer, Cystic Fibrosis and IBD. The biobanks are an expanding resource of highly characterized Organoids for different organ systems and include both genetic and clinical data of the patient.
Clinical application of HUB organoids by generating organoids from individual patients provides a next generation tool for predictive diagnostics, designing targeted and personalized therapies as well as clinical patient stratification.
Animal Derived Organoids
Organoids derived from mice, rats, dogs, and mini pigs allow for in vitro toxicology and research that will provide high trough put while maintaining in vivo relevance. In addition, to providing a direct comparison between animal and humans studies it will help decrease the use of animals in medical research.